Premium
Correlation between the proliferative response to granulocyte colony‐stimulating factor and the positivity of transferrin receptor in acute myeloblastic leukemia cells
Author(s) -
Motoji Toshiko,
Mineshima Michio,
Watanabe Masahiko,
Takanashi Minoko,
Masuda Michihiko,
Oshimi Kazuo,
Mizoguchi Hideaki
Publication year - 1991
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.1041480313
Subject(s) - acute myeloblastic leukemia , transferrin receptor , granulocyte colony stimulating factor receptor , receptor , transferrin , granulocyte colony stimulating factor , immunology , receptor expression , medicine , leukemia , biology , chemotherapy
The use of granulocyte colony‐stimulating factor (G‐CSF) after chemotherapy for acute myeloblastic leukemia (AML) has been reported. However, there is a drawback in that G‐CSF may stimulate the proliferation of AML progenitors. To determine the parameter(s) indicative of responsiveness of AML blasts to G‐CSF, various surface phenotypes of blasts were examined in relation to the blast colony formation stimulated by G‐CSF in 39 AML patients. A correlation was found only with transferrin receptor positivity among the various phenotypes studied. The population mean of percentages of transferrin receptor‐positive blasts in the group responding to G‐CSF in vitro was significantly higher than that of blasts in the group not responding to G‐CSF. A further correlation was found between transferrin receptor positivity and the number of G‐CSF receptors on the blasts; that is, blasts expressing more G‐CSF receptors have greater transferrin receptor positivity. In our previous study, we observed that blasts with a large number of G‐CSF receptors produce more colonies in response to G‐CSF. These results indicated that blasts expressing more transferrin eceptors have a large number of G‐CSF receptors and may show more active proliferation in response to G‐CSF. Therefore, the proliferative response of blasts to G‐CSF can be predicted by examining transferrin receptor positivity. The clinical use of G‐CSF in AML patients may be recommended when the patient's blasts have a low level of transferrin receptor expression. The measurement of transferrin receptors on blasts, instead of the rather complicated G‐CSF receptor determination, would be a useful indicator for the safer application of G‐CSF in AML patients.